Elutia Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
51
- Stock Symbol
-
ELUT
- Investments
-
1
- Share Price
-
$2.32
- (As of Thursday Closing)
Elutia General Information
Description
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Contact Information
Website
www.elutia.comCorporate Office
- 12510 Prosperity Drive
- Suite 370
- Silver Spring, MD 20904
- United States
Corporate Office
- 12510 Prosperity Drive
- Suite 370
- Silver Spring, MD 20904
- United States
Elutia Timeline
Elutia Stock Performance
As of 17-Apr-2025, Elutia’s stock price is $2.32. Its current market cap is $94.8M with 40.9M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.32 | $2.10 | $1.87 - $5.24 | $94.8M | 40.9M | 43K | -$1.86 |
Elutia Financials Summary
As of 31-Dec-2024, Elutia has a trailing 12-month revenue of $24.4M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 126,653 | 126,653 | 61,267 | 88,178 |
| Revenue | 24,375 | 24,375 | 24,745 | 23,849 |
| EBITDA | (45,892) | (45,892) | (31,677) | (27,297) |
| Net Income | (53,949) | (53,949) | (37,656) | (32,897) |
| Total Assets | 36,127 | 36,127 | 43,428 | 68,841 |
| Total Debt | 24,736 | 24,736 | 23,952 | 24,492 |
Elutia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Elutia Comparisons
Industry
Financing
Details
Elutia Competitors (7)
One of Elutia’s 7 competitors is Vivex Biologics, a Private Equity-Backed company based in Miami, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vivex Biologics | Private Equity-Backed | Miami, FL | ||||
| Organogenesis Holdings | Pending Transaction (M&A) | Canton, MA | ||||
| Mimedx | Corporation | Marietta, GA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA |
Elutia Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Elutia Patents
Elutia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10293084-B2 | Extracellular matrix (ecm) structures for tissue regeneration | Active | 10-May-2007 |
Elutia Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Elutia Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Elutia Investments (1)
Elutia’s most recent deal was a Buyout/LBO with Cormatrix Cardiovascular. The deal was made on 31-May-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cormatrix Cardiovascular | 31-May-2017 | Buyout/LBO | Surgical Devices |
Elutia ESG
Risk Overview
Risk Rating
Updated June, 26, 2021
34.92 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile
Pharmaceuticals
Industry
of 947
Rank
Percentile
Biotechnology
Subindustry
of 427
Rank
Percentile
Elutia Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cormatrix Cardiovascular | Roswell, GA | 2001 |
Elutia FAQs
-
When was Elutia founded?
Elutia was founded in 2015.
-
Where is Elutia headquartered?
Elutia is headquartered in Silver Spring, MD.
-
What is the size of Elutia?
Elutia has 51 total employees.
-
What industry is Elutia in?
Elutia’s primary industry is Biotechnology.
-
Is Elutia a private or public company?
Elutia is a Public company.
-
What is Elutia’s stock symbol?
The ticker symbol for Elutia is ELUT.
-
What is the current stock price of Elutia?
As of 17-Apr-2025 the stock price of Elutia is $2.32.
-
What is the current market cap of Elutia?
The current market capitalization of Elutia is $94.8M.
-
What is Elutia’s current revenue?
The trailing twelve month revenue for Elutia is $24.4M.
-
Who are Elutia’s competitors?
Vivex Biologics, Organogenesis Holdings, Mimedx, Amgen, and Genentech are some of the 7 competitors of Elutia.
-
What is Elutia’s annual earnings per share (EPS)?
Elutia’s EPS for 12 months was -$1.86.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
